Objective: This study aims to investigate whether single-nucleotide polymorphisms (SNPs) CYP2C9 and VKORC1 can be used to adjust effective warfarin treatment for aboriginal Taiwanese population. Materials and Methods: This study investigates the association of SNPs CYP2C9 and VKORC1 and clinical factors [sex, age, and body mass index (BMI)] with variable responses to warfarin treatment in 42 aboriginal and 63 Han Taiwanese people. Results: The incidence of the VKORC1-1639AA genotype and the effective warfarin dosage were similar in the populations studied. However, the required dosage of warfarin for women with VKORC1-1639AA polymorphism was significantly lower than for their male counterparts. Conclusion: This result provides guidance for prescribing an effective warfarin dosage for aboriginal and Han Taiwanese patients with genetic polymorphisms.
Introduction
Warfarin is the most common oral anticoagulant for patients with cardioembolic stroke and for secondary prevention of venous thromboembolism, acute myocardial infarction, embolic stroke, and chronic atrial fibrillation [1e3]. However, the dosage required for a therapeutic effect varies widely among different people and ethnic groups [4e7] . The therapeutic dosage range of warfarin is narrow, and there is a risk of serious bleeding with overdosing [8] . Complex factors including age, body mass index (BMI), sex, intake of vitamin K, concomitant diseases, and drugs influence the effective warfarin dosage [8e10] . In addition to the potential influence of these clinical variables, inherited differences in drug metabolism and drug targets can also affect the efficacy and toxicity of warfarin.
Twenty-nine genes are suspected to mediate the effects of warfarin, mainly contributing to the pharmacokinetics and pharmacodynamics of the drug [11] . Most pharmacogenomic research on warfarin has been based on association studies examining polymorphisms in the cytochrome p450 2C9 (CYP2C9) and vitamin K epoxide reductase complex 1 (VKORC1) genes. Common variants in the CYP2C9 and VKORC1 genes, combined with a subset of environmental determinants, account for approximately 50e60% of the variability in the required warfarin dosage [11, 12] .
The CYP2C9 gene, which encodes for the key enzyme that metabolizes warfarin, has a number of functional variants associated with lower warfarin requirements. For example, CYP2C9*2 and CYP2C9*3 differ in prevalence among different ethnic groups [13e 16]. However, these two CYP2C9 genetic polymorphisms cannot account for lower warfarin requirements among Chinese patients because they rarely occur in Asian populations [17e19] . Mutation in the coding region of the VKORC1 gene has been shown to cause multiple coagulation factor deficiency type 2 and warfarin resistance [20, 21] . Several single-nucleotide polymorphisms (SNPs) of the VKORC1 gene also correlate with variable warfarin dosages and adverse bleeding events [22, 23] . Yuan et al reported that the VKORC1 promoter polymorphism (-1639G>A) was present in all warfarin-sensitive patients. They showed that the frequency of the AA genotype was significantly higher in Han Chinese than in a Caucasian population receiving warfarin. Later, several other studies also demonstrated that the VKORC1 promoter polymorphism (-1639G>A) is a major determinant of warfarin response in anticoagulated patients of various ethnic groups [18,24e28] .
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Ethics statement
This research was approved by the Institutional Review Board of Buddhist Tzu Chi Medical Center (IRB096-58). All patients who participated in this study provided written informed consent before blood sampling for genetic analysis as well as for publication of the clinical data.
Recruited patients
From 2006 to 2009, researchers recruited patients receiving maintenance warfarin therapy for secondary stroke prevention who had a stable international normalized ratio (INR) between 1.5 and 3 for 3 months. Anticoagulation of all patients was stably controlled with a target INR between 1.5 and 3, according to different indications, for the prevention of secondary stroke [2, 30] .
Indicators for warfarin treatment included different stroke subtypes including cardioembolic infarction, embolic infarction of unknown origin, basilar artery occlusion with brain-stem infarction, and stroke in evolution. The stroke subtype of the recruited patients was diagnosed and clarified by magnetic resonance imaging of the brain. Cardioembolic stroke was verified by examining the thrombus in the left atrium of the heart through a transesophageal endoscopic examination. Stroke in evolution was defined clinically as neurological deficit progression within 48 hours after a stroke.
Concomitant liver function tests, including evaluating levels of aspartate transaminase (AST) and alanine transaminase (ALT) [31] , were done, and patients with moderate to severe liver function impairment were excluded. A questionnaire based on principles of reference [32] was completed by recruited patients or their families; patients with poor compliance to warfarin therapy were also excluded based on the answers provided by the patients on the questionnaire. The ethnicity of patients was included in the questionnaire. A participant was considered Han Taiwanese or aboriginal Taiwanese if his or her parents were both of that same ethnic group.
Clinical data collection consisted of a review of inpatient and outpatient medical records. Retrospectively, researchers collected clinical factors such as age, sex, body weight, height, concurrent medications, and concomitant diseases, which could influence the response to warfarin. The average warfarin maintenance dosage was the mean dosage between two consecutive INR values collected from the medical records. Any adverse bleeding events during anticoagulation were recorded in the medical records. Venous blood was sampled from participants for genomic DNA extraction and genetic analysis.
Genomic DNA extraction
Approximately 10 mL of venous blood was drawn from each patient using ethylenediaminetetraacetic acid (EDTA) tubes and sent to a laboratory for genomic DNA extraction. Leukocyte DNA was isolated using a commercial DNA purification kit (QIAamp DNA Mini Kit; QIAGEN, Hamburg, Germany) from 10 mL of venous blood, according to the manufacturer's instructions. After purification, genomic DNA integrity was verified through electrophoresis on 1% TriseacetateeEDTA agarose gel. The concentration of genomic DNA was measured spectrophotometrically at 260 nm.
DNA sequencing
DNA sequences of CYP2C9 and VKORC1 were analyzed according to the National Center for Biotechnology Information database. Primers were used to detect CYP2C9*3 allelic variants in exon 7 of the CYP2C9 gene and -1639G>A variants in the VKORC1 promoter regions as listed in Table 1 . Primers were designed using the primer 3 polymerase chain reaction primer program. Genotypes of CYP2C9*3 and VKORC1-1639G>A were extracted using the direct DNA-sequencing method (3700 DNA analyzer; Applied Biosystems, Grand Island, NY) at the National Yang-Ming University Genome Research Center. Sequence variants were directly analyzed by DNA sequence viewer software (Chromas Lite v2.01). This research did not generate new gene-sequencing data.
Statistical analysis
The warfarin maintenance dose was compared across VKORC1-1639 genotypes and ethnic groups using Student unpaired t test. The Chi-square test was used to analyze sex across the VKORC1 genotype. A simple regression test correlated the warfarin dose with variables including age, sex, and BMI. The results are reported as mean AE standard deviation. A p value < 0.05 was considered to be significant.
Results
Patient characteristics
The frequencies of CYP2C9*3 and VKORC1-1639G>A sequence variants were analyzed in 105 stroke patients regularly receiving warfarin with stable INR monitoring for 3 months. The mean age of these patients was 65.6 AE 2.2 years (range: 46e84 years). The sex Table 1 Primers used for amplification and sequencing of polymorphisms of the CYP2C9 and VKORC1 genes.
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Forward primer Reverse primer Taiwanese  (Table 2 ). All participants in this study met strict recruiting criteria, and all aborigine patients had a pure genetic background. Ethnicity was determined after the patients signed informed consents. Participants were required to have parents who were both Han Taiwanese or both aboriginal Taiwanese to be eligible for this study.
The medical indicators for warfarin therapy were cardioembolic stroke (83.8%), basilar artery occlusion with brain-stem infarction (11.4%), and stroke in evolution (4.8%). The average stable target INR in the recruited patients was 2.19 AE 0.05 (range: 1.60e2.69) and was calculated according to standard guidelines [2, 3, 30, 33] . The average maintenance dosage of warfarin was the mean dosage during the period when two consecutive INR values were collected from the medical records. The mean daily maintenance dose of warfarin was 3.15 AE 0.3 mg (range: 1e6 mg) to achieve an INR value 2.19 AE 0.05 (range: 1.60e2.69).
Researchers also recorded and analyzed concomitant chronic illnesses and concurrent administration of drugs in recruited patients, which could influence the warfarin maintenance dosage [9, 34] . There was an average of 2.5 AE 0.2 concomitant chronic disorders per patient (range: 1e4 disorders). The most common concomitant disorders were hypertension (63.8%), hyperlipidemia (56.2%), chronic atrial fibrillation (9.5%), diabetes mellitus (11.4%), and coronary artery disease (12.4%), which are all risk factors for cerebrovascular disorders. The mean number of concurrent medications taken by the recruited patients was 3.4 AE 0.3 (range: 1e6).
Interactions with concurrent medications with warfarin were analyzed according to a review lecture by Holbrook et al, and included atorvastatin (n ¼ 13), phenytoin (n ¼ 5), omeprazole (n ¼ 7), diltiazem (n ¼ 6), allopurinol (n ¼ 5), fenofibrate (n ¼ 1), and nonsteroidal anti-inflammatory drugs (n ¼ 3) [9] .
Required warfarin dosage for Han and aboriginal Taiwanese patients is similar
The mean daily warfarin dose required to maintain a stable INR between 1.60 and 2.69 among patients was 3.15 AE 0.3 mg (range: 1e6 mg). Student unpaired t test showed that the mean warfarin dosage was similar for Han and aboriginal Taiwanese patients (3.0 AE 0.4 mg/day for Hans and 3.3 AE 0.4 mg/day for aborigines, p ¼ 0.51) to achieve a stable INR.
Frequency of CYP2C9 and VKORC1-1639G>A variants in warfarin-treated Han and aboriginal Taiwanese patients is similar
The CYP2C9*3 and VKORC1-1639G>A SNPs were selected for analysis because these two genetic polymorphisms have been reported to be the main contributors to variable warfarin responses in different populations [25, 27] . All Taiwanese Han and aboriginal patients treated with warfarin carried the CYP2C9*1 variant; no CYP2C9*3 variant was recorded. The VKORC1-1639AA genotype was found in the majority of patients (89/105, 84.8%). Among them, 82.5% (52/63) of Han and 88% (37/42) of aboriginal Taiwanese patients were carriers ( Table 3 ). The remaining patients had the VKORC1-1639AG genotype (17.5% for Han Taiwanese and 12% for aboriginal Taiwanese patients). The VKORC1-1639GG genotype was not detected.
Association analysis of the VKORC1-1639G>A genotype with warfarin dosage
To evaluate the association of the VKORC1 genotype with the daily warfarin dosage, the mean warfarin dosages were analyzed and compared against different VKORC1 genotypes using Student unpaired t test. Patients with VKORC1-1639AA had significantly lower dosage requirements (mean: 2.51 AE 0.2 mg/day; range: 1e 5 mg/day, p < 0.001) than those with the heterozygous VKORC1-1639AG genotype (mean: 4.28 AE 0.2 mg/day, range: 4e6 mg/day) ( Table 3 ). The mean required warfarin dosage was similar for both Han (2.33 mg/day) and aboriginal Taiwanese patients (3.19 mg/day) with the AA genotype (p ¼ 0.08).
Association of age, sex, and BMI with effective warfarin dosage
Consistent with the results of previous studies, data from this study showed that the warfarin dosage requirement correlated negatively with age, decreasing by 1.1 mg per decade within the age range of 45e85 years, irrespective of body weight, ethnicity, or sex differences (Fig. 1) . To examine the correlation between sex and warfarin dosage, the dosage was compared between men and women with the same VKORC1-1639AA genotype. The warfarin dosage required to achieve an INR between 1.60 and 2.69 (p < 0.01) in women was significantly lower (n ¼ 31, 1.96 mg/day) than that required to achieve the same INR in men (n ¼ 58, 3.07 mg/day) (Fig. 2) . This difference had no relation to age and could not be explained by differences in the BMI between men and women (p ¼ 0.51). No woman had the VKORC1-1639AG genotype among our recruited patients.
Discussion
This study demonstrated that the frequency of the CYP2C9 and VKORC1-1639G>A polymorphisms in aboriginal Taiwanese patients is similar to those in Han Taiwanese patients, and verified that VKORC1-1639AA can also indicate a need for a lower warfarin maintenance dosage to prevent secondary stroke in Taiwanese aborigines. The warfarin maintenance dosage was negatively correlated with age. In addition, researchers discovered that the maintenance dosage was lower for women than men carrying the same VOKRC-1639AA polymorphism.
Consistent with previous studies for the Asian populations [16] , the CYP2C9*3 polymorphism was not present in the Han Taiwanese patients recruited for this study. The data also demonstrated that the aboriginal Taiwanese people, who have a different genetic background from Hans, do not carry this polymorphism either. All patients had the CYP2C9*1 wild-type genotype. Thus, the CYP2C9 genetic polymorphism cannot explain variable warfarin responses observed in the Taiwanese population.
The majority of patients, both in the Han (82.5%) and in the aboriginal (88%) population, had the VKORC1-1639AA genotype. No significant difference in the frequency of VKORC1-1639AA was observed between the two populations studied. Patients with the VKORC1-1639AA genotype required a significantly lower daily warfarin dose (2.51 AE 0.2 mg/day) than patients with the VKORC1-1639AG genotype (4.28 AE 0.2 mg/day, p < 0.001). The mean warfarin dosage requirement was similar between Han (2.33 AE 0.6 mg/day) and aboriginal Taiwanese patients (3.19 AE 1.2 mg/day) who had the same VKORC1-1639AA genotype (p ¼ 0.08). The differences in warfarin sensitivity between patients with the VKORC1-1639AA and AG genotypes could be explained by changes in VKORC1 promoter activity. Yuan et al demonstrated that VKORC1 promoter activity is decreased by the VKORC1-1639AA polymorphism. Decreased levels of VKORC1 messenger RNA can lead to lower VKORC1 activity, and ultimately result in a lower required warfarin dosage for appropriate anticoagulation [35] .
Previous studies have shown that the warfarin dosage requirement diminishes with age. Older patients show increased sensitivity to the anticoagulant effects of this drug [36] . The cause of this phenomenon is unknown, and may be due to a combination of pharmacokinetic and pharmacodynamic factors. This study also found that the warfarin dosage requirement was reduced by approximately 1.1 mg per decade within the age range of 45e85 years. This finding confirms those of previous studies and suggests that physicians prescribe a lower warfarin dosage for elderly Taiwanese patients because of a higher risk of bleeding [10, 34, 36] .
Whether sex is a factor contributing to variability in patient responses to warfarin remains controversial. Regardless of genetic polymorphisms, some previous studies reported no gender differences for the warfarin dosage in atrial fibrillation patients [37] and Han Chinese patients [38] , whereas others indicated that women were more sensitive to warfarin than men [39e41]. This study found significantly different warfarin dosage requirements between men (3.07 mg/day) and women (1.96 mg/day, p < 0.01) with the same VKORC1-1639AA genotype. The gender difference for VKORC1-1639AA carriers could not be explained by differences in BMI (p ¼ 0.51). Several factors have been studied to explain gender differences in the pharmacokinetics of drugs, including the rate of gastric emptying, intestinal transit time, expression of gut enzymes, total body water space, muscle mass, organ blood flow, organ function, body fat, and hepatic metabolism [42] . Further research is necessary to elucidate the cause of gender differences in the warfarin dosage for the VKORC1-1639AA population.
Two patients demonstrated adverse bleeding during the course of warfarin therapy, although they had stable INR monitoring. One patient presented with upper gastrointestinal bleeding, and the other demonstrated spontaneous retroperitoneal hematoma. Warfarin treatment was withdrawn from these two patients immediately when bleeding was noted. Two other patients showed variable warfarin responses (INR between 1.12 and 4.02) with a steady warfarin maintenance dosage (approximately 1.5e1.75 mg/ day). However, no hemorrhage was detected, even in patients with unstable INRs. These four patients had the VKORC1-1639AA genotype; therefore, other genetic factors in addition to VKORC1-1639AA polymorphism may contribute to the variable warfarin responses observed in these cases. This study concludes that the VKORC1-1639G>A genotype was the primary polymorphism in the VKORC1 gene contributing to the need for a reduced warfarin dosage in the Taiwanese population, including the genetically different aboriginal population. The frequency of the VKORC1-1639G>A genotype is similar between Han and aboriginal Taiwanese patients, and the VKORC1-1639AA genotype correlates strongly with a lower daily warfarin dose in both Han and aboriginal Taiwanese patients. Women require a lower warfarin dosage than men in the VKORC1-1639AA genotype group. Combining genetic information of VKORC1-1639G>A polymorphism with the age and sex of patients may enable physicians to choose an optimal warfarin maintenance dosage for members of the Taiwanese population. The results will not only benefit Taiwanese aborigines, but will also be valuable for clinicians prescribing warfarin to other patients with Austronesian genetic backgrounds.
